sector medic suppli devic
 strong cap impress
go get tougher
messag report result larg line
expect solidli ahead overli conserv street forecast revenu
rise yoy beat consensu perform
show compani strong momentum past month carri
believ investor expect like closer forecast
consensu result anticip mute stock reaction beat
magnitud would normal entail look ahead expect underli cgm
market fundament remain robust see growth moder
back half year comp toughen
strong momentum continu revenu rose cc yoy
beat consensu compani busi remain robust quarter
sale top street expect mark compani
seventh consecut quarter strong gain domest growth
modestli level saw comp tougher dexcom
continu work toward shift sale channel dme pathway pharmaci
option avail custom base improv patient access
come price howev manag reiter reduc revenu per
patient like headwind thu far price headwind
off-set ramp volum profit suffer
dynam gm yoy launch new lower cost transmitt
boost gross margin back exit year
elsewher intern busi came littl light quarter ou
revenu miss grew cc manag chalk
lumpi order distributor direct sale busi show sign
slowdown product level basi global sensor sale came
consensu drove major beat hardwar sale mix
beat transmitt somewhat off-set miss receiv
go forward expect hardwar growth continu lag behind sensor
promot broader access hardwar rebat pharmaci channel
longer term transit featur integr sensor/transmitt
fulli dispos increas use mobil app rather dedic receiv
like put addit pressur hardwar compon busi
top line strong opex manag off-set gm pressur drove bottom
line beat report gross margin yoy
consensu gross margin neg impact acceler invest
increment manufactur capac meet strong demand well shift mix
toward pharmaci channel intern market elsewher sg expens
rose yoy sale street estim meanwhil
 spend increas yoy revenu ahead consensu
combin drove net incom per share vs street
back strong result manag rais revenu outlook
guidanc call full year sale rise
previous seri big beat backdrop
view overli conserv guidanc see revis outlook bracket
estim come quarter realist key question stock
view whether buy-sid expect remain high recent seri
blow-out result even comp toughen guidanc presum consensu rise
level leav less obviou upsid potenti
page analyst certif import disclosur
incom statement manag reiter gross margin forecast
compani continu pull forward invest capac expans meet
except volum demand see moment gross margin improv
new capac come on-line new transmitt roll oper ebitda
margin expect come respect manag
previou forecast
pipelin front eye alreadi shift manag remain
confid late limit launch next-gen sensor broader roll-out slate
meantim plan launch give
physician increas flexibl allow patient trial system short period
decid whether go cgm full time compani also slate kick clinic
trial later year studi impact cgm in-hospit glucos manag
gestat diabet outsid pipelin pump partner continu target
fda approv control-iq hybrid-clos loop system
model call post adjust ep total revenu
cc compar prior estim
respect base revis estim share trade ntm
revenu level commensur top-lin growth outlook believ
compani deliv result maintain neutral rate
page analyst certif import disclosur
san diego ca base medic devic compani focus develop
continu glucos monitor cgm technolog aid treatment
manag diabet compani launch first cgm system st
follow recent fda approv new system sixth gener
cgm technolog last twelv year time led way
cgm grown world-wide market posit impact live
believ continu glucos monitor cgm way becom standard
care insulin-depend diabet nearli year sinc introduct
countless studi valid advantag cgm tradit point-in-tim
blood glucos test reduc critic factor manag diabet
yet despit compel clinic evid support use estim penetr
remain rel low today approxim type popul less
insulin-intens type patient mani factor contribut
lacklust adopt view includ inconsist sensor accuraci conveni
qualiti life issu high increment cost therapi recent advanc
address mani histor drawback technolog pave way
bullish outlook cgm adopt abil sustain
leadership posit market time believ field enter disrupt
phase spur rapid influx new technolog feedback physician
patient survey suggest could risk share price
perspect dynam current take back seat posit market fundament
still see long-term risk given share current trade
see limit potenti upsid prefer wait better entri point
valu primarili ev/sal basi use repres group small-
to-mid cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim current trade ntm
sale toward high end rang comp group see
valuat fair thu assign share neutral rate
upsid risk rate includ cgm penetr ramp faster expect
product pipelin could improv competit popul open
opportun potenti adopt competit cgm technolog could
fall short street expect
downsid risk rate includ greater expect adopt competit
cgm technolog price pressur reduc sale margin failur
continu solidli execut oper
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
revenu compon
compani report guggenheim secur llc estim
page analyst certif import disclosur
